Product Description
Mechanisms of Action: Tubulin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Sarcoma
Phase 2: Ovarian Cancer|Non-Small-Cell Lung Cancer
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01193595 |
TCD11379 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2014-10-01 |
2019-03-19 |
Treatments |
|
NCT01293630 |
TCD11270 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2013-10-01 |
2019-03-19 |
Treatments |
|
NCT00719524 |
TCD10620 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2013-02-01 |
2019-03-18 |
Treatments |
|
NCT01095302 |
TCD11089 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2011-12-01 |
2019-03-19 |
Treatments |
|
NCT00968916 |
TED10967 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2011-08-01 |
2019-03-19 |
Treatments |
|
NCT01021150 |
TCD11088 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2011-05-01 |
2019-03-19 |
Treatments |
|
NCT01063946 |
BEX6587 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2011-03-01 |
2019-03-19 |
Treatments |
|
NCT01907685 |
TCD6295 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2011-02-01 |
2019-03-19 |
Treatments |
|
NCT01332656 |
OPSALIN | P2 |
Completed |
Ovarian Cancer |
2014-07-01 |
2019-03-19 |
Treatments |
|
2010-024631-16 |
OPSALIN | P2 |
Completed |
Ovarian Cancer |
2013-01-02 |
2022-03-13 |
Treatments |
|
2010-019384-11 |
DISRUPT | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2012-10-02 |
2022-03-13 |
Treatments |
|
NCT01263886 |
DISRUPT | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2012-03-01 |
2019-03-19 |
||
2007-003592-39 |
2007-003592-39 | P3 |
Completed |
Sarcoma |
2013-04-17 |
2022-03-12 |
Treatments |
|
NCT00699517 |
EFC10145 | P3 |
Completed |
Sarcoma |
2013-04-01 |
2019-03-18 |
Treatments |